TCRX Share Price Performance
US$1.75
-4.19 (-70.54%)
Price US$1.75
Share PriceUS$1.75
TCRX Community Narratives
There are no narratives available yet.
Recent TCRX News & Updates
No updates
TScan Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.32
- Gross Margin
- -121.15%
- Net Profit Margin
- -2,974.08%
- Debt/Equity Ratio
- 15.3%
TScan Therapeutics, Inc. Competitors
About TCRX
- Founded
- 2018
- Employees
- 201
- CEO
- WebsiteView website
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading